Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$22.31 - $26.7 $203,021 - $242,970
-9,100 Reduced 90.1%
1,000 $23,000
Q4 2023

Feb 14, 2024

SELL
$13.82 - $19.13 $105,032 - $145,388
-7,600 Reduced 42.94%
10,100 $186,000
Q3 2023

Nov 14, 2023

BUY
$14.02 - $17.71 $88,326 - $111,573
6,300 Added 55.26%
17,700 $249,000
Q2 2023

Aug 14, 2023

BUY
$17.0 - $21.58 $161,500 - $205,009
9,500 Added 500.0%
11,400 $215,000
Q4 2022

Feb 14, 2023

SELL
$16.0 - $25.45 $515,200 - $819,490
-32,200 Reduced 94.43%
1,900 $34,000
Q3 2022

Nov 14, 2022

SELL
$15.9 - $29.56 $518,340 - $963,656
-32,600 Reduced 48.88%
34,100 $611,000

Others Institutions Holding XOMA

About XOMA Corp


  • Ticker XOMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,450,800
  • Market Cap $305M
  • Description
  • XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolog...
More about XOMA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.